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Abstract
Background and Aims: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When
administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2
diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or
without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.
Methods: Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c)
7.160.3% (5464 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4
weeks in a randomized crossover study.
Results: HbA1c (P= 0.007) and fructosamine (P= 0.02) decreased modestly, without significant time-treatment interactions
(both P= 0.4). Blood urea increased (P,0.001) without a significant time-treatment interaction (P= 0.8), but creatinine and
estimated glomerular filtration rate (eGFR) were unchanged (P$0.5). Red blood cells, hemoglobin, hematocrit, and albumin
modestly decreased (P#0.02), without significant time-treatment interactions (P$0.4). Body weight and plasma electrolytes
remained unchanged (P$0.2).
Conclusions: Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-
controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.
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Introduction
Impaired insulin secretion contributes to hyperglycemia in type
2 diabetes. Glucagon-like peptide (GLP)-1 is secreted from
intestinal L-cells in response to nutrients and is rapidly degraded
by dipeptidyl peptidase (DPP)-4. GLP-1 contributes to myriad of
metabolic effects, including insulin secretion, beta cell prolifera-
tion, slowing of gastric emptying and increased satiety; all are
desirable features of type 2 diabetes therapy [1–3]. GLP-1 receptor
agonists and DPP-4 inhibitors are used to treat type 2 diabetes
patients. However, enhancement of GLP-1 secretion with meals
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has the advantage of increasing GLP-1 concentrations in the
intestinal milieu, where it is believed to act on vagal neurons and
mediate its central effects. Moreover, the cleaved GLP-1 product
(9–36), which suppresses hepatic glucose production and exerts
antioxidant action [4], may also be enhanced by agents that
increase GLP-1 secretion.
The amino acid L-glutamine is an efficacious GLP-1 secreta-
gogue for the colonic L-cells model GLUTag [5] and primary
murine colonic culture [6]. Well-controlled type 2 diabetes
patients have intact GLP-1 response to glutamine ingestion [7]
and glutamine (30 g) or glutamine (15 g) in combination with the
DPP-4 inhibitor sitagliptin (100 mg) decreases postprandial
glycaemia and increases circulating insulin and GLP-1 when
administered with a meal [8].
The primary aim of this randomized crossover study was to
determine the glycemic effect of 4 weeks of glutamine (15 bd)
supplementation with sitagliptin (100 mg/d) or placebo in type 2
diabetes patients treated with metformin. We hypothesized that
both treatments will decrease hemoglobin A1c (HbA1c) and
fructosamine, with a greater effect exhibited in the combined
glutamine-sitagliptin treatment, due to more pronounced post-
prandial increases in GLP-1 in the circulation. The secondary aim
was to evaluate the safety of glutamine supplementation.
Methods
This study was conducted according to the principles expressed
in the declaration of Helsinki. The study was approved by the
Human Research and Ethics Committee at St Vincent’s Hospital,
Sydney. All participants gave written informed consent prior to
commencement of the study. The protocol for this study and
supporting CONSORT checklist are available as supporting
information (Checklist S1 and Protocol S1). The study was
registered at www.ClinicalTrials.gov (NCT00673894).
Participants
Type 2 diabetes patients were recruited through advertisements
at the St Vincent’s Hospital precinct, Sydney and in local
newspapers. Participants were recruited and followed between
January 2010 and November 2011. Inclusion criteria were age 40–
70 years, short diabetes duration (5 years or less), treatment with
metformin in a stable dose (#2000 mg/d) for at least 3 months,
HbA1c 6.5–9% (48–75 mmol/mol), BMI #40 kg/m2 and stable
body weight in the preceding 6 months (62 kg). Exclusion criteria
were treatment with oral hypoglycemic agents other than
metformin, ethanol intake of 40 g/d or more, liver or kidney
disease or abnormal full blood count, renal or liver function tests,
use of weight loss medications, previous bowel surgery or
documented malabsorption. Of the 108 individuals pre-screened
for eligibility over the telephone, 22 were invited to a screening
visit at the clinic. Fifteen participants (Caucasian, 10 men) were
included and 13 (9 men) completed the study (Figure 1).
Trial design
The primary endpoints of this study were the glycemic control
markers HbA1c and fructosamine, determined as below (Labora-
tory Analyses). Two treatments were considered in the study and
randomized crossover design was applied (Figure 2). Participants
received glutamine (15 g bd) with sitagliptin (100 mg) or placebo.
Treatment allocation order was randomized according to a
randomization sequence provided by Merck. A nurse not involved
directly with the study was in charge of distribution of sequentially
numbered containers of sitagliptin or placebo to participants and
kept a list with participants’ identification numbers and treatment
sequence allocation. Study participants, investigators and nurses
were blinded to the treatment allocation order. HbA1c and
fructosamine levels were determined at baseline (control). Partic-
ipants were then administered their first treatment over a 4 week
period. Endpoint levels were then determined. This period was
followed by a 4–6 week washout period. The second treatment
trial then followed using the same protocol.
Procedures
Screening study was performed at the Clinical Research Facility
at the Garvan Institute of Medical Research and included weight,
height and blood pressure measurements, and medical examina-
tion. Blood was drawn for renal and liver function tests, full blood
count, and HbA1c. Participants were provided with lead-in
placebo tablets and instructed to take 1 tablet 15 min before
breakfast for two weeks preceding each baseline study (lead-in,
Figure 2). On day 0 and 4-weeks of each study participants
Figure 1. Flow of participants in the study. *Other reasons include
participant not able to take time off work or other engagements (n = 3),
family not approving (n = 2), underlying disease (n = 3), weight unstable
or actively trying to lose weight (n = 2), change of mind (n = 1) and
inability to provide informed consent (n = 1).
doi:10.1371/journal.pone.0113366.g001
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attended the Clinical Research Facility fasting from 22:00 h the
previous night for a meal challenge (Figure 2). Weight, height and
blood pressure were measured and indirect calorimetry performed
following 30 min of supine rest (Parvomedics, UT, USA). Heart
rate was measured by a SphygmoCor device (AtCor Medical,
Australia). A large-bore intravenous indwelling cannula was
inserted into a large antecubital vein for blood sampling. Blood
was collected for glycemic markers, full blood count, liver and
renal function tests and glutamine. After drawing blood twice
10 min apart at baseline for blood glucose, serum insulin and
plasma GLP-1 measurements, the lead-in placebo tablet on day 0
or the tablet taken during the study on the 4-weeks visits was taken
in 300 ml of cold water and followed by a low fat meal comprising
33 g Wheat-Bix (Sanitarium) and 250 mL low fat milk, providing
230 kcal (37 g carbohydrate, 1.3 g fat and 16 g protein), as
described previously [8]. Meal was consumed within 8 min and
blood samples were drawn at 15, 30, 45, 60, 90, 120, 150 and
180 min. At completion of A-Baseline and B-Baseline studies
(Figure 2), participants were provided with 4 weeks’ worth of study
tablets and L-glutamine (Cambridge Commodities, Cambridge,
United Kingdom) and instructed to fill compliance lists and diet
diaries. At home, during A and B studies, participants took
sitagliptin (100 mg) or placebo 15 min prior to L-glutamine (15 g),
followed by their normal breakfast. L-glutamine (15 g) was taken
again 15 min prior to dinner. Meal challenge at 4 weeks of A and
B studies was repeated, but participants received not only the
tablet they had been taking in the preceding 4 weeks, but also
glutamine (15 g) followed by the meal (Figure 2).
Compliance, diet and physical activity monitoring
Participants were instructed not to change their eating habits
and physical activity levels during the study to avoid confounding
effects of diet and physical activity on glycemic control. They
recorded food and drinks consumed during 6 days in the lead-in
and study periods, filled daily compliance lists and were contacted
by the research nurse weekly. On clinic study days, participants
returned residual tablets and glutamine, and intake of protein-rich
food items and physical activity level were assessed by 7-day
questionnaires.
Laboratory analyses
HbA1c was analyzed by cation-exchange HPLC using the
Variant II analyzer (Bio-Rad Laboratories, Gladesville, NSW,
Australia), fructosamine by a nitro-blue tetrazolium method,
fasting plasma glucose by a hexokinase method and other
biochemistry tests using standard methods on a Roche Modular
analyzer using Roche reagents (Roche Diagnostics Australia,
Castle Hill, NSW Australia). Full blood count was measured using
a Beckman Coulter analyzer (Beckman-Coulter, Gladesville NSW,
Australia). Whole blood glucose was assayed immediately after
collection by the glucose oxidase electrode (Yellow Springs
Instrument Company; Life Sciences). Insulin was measured in
sera stored at280uC by radioimmunoassay (Millipore, St Charles,
USA). Blood samples for plasma glutamine were collected into
chilled heparin-coated tubes and immediately centrifuged (7 min
at 4100 6 g), snap frozen and stored at 280uC until analysis.
Plasma glutamine was measured by reverse phase ultra-perfor-
mance liquid chromatography with UV detection (Acquity UPLC,
Waters, Rydalmere, NSW, Australia). Plasma was deproteinized
with 10% s-sulphosalicylic acid containing norvaline as an internal
standard. Amino acids were then derivatized with 6-aminoquino-
lyl-N-hydroxysuccinimidyl carbamate and separated by gradient
elution. Blood samples for total and active GLP-1 were collected
into chilled EDTA-coated tubes (with DPP-4 inhibitor and trasylol
in the active GLP-1 testing tube) and immediately centrifuged
(7 min at 4100 6 g), snap-frozen and stored at 280uC until
analysis. Total and active GLP-1 concentrations were measured as
previously described [8]. Briefly, total GLP-1 was measured by
radioimmunoassay after extraction of plasma with 70% ethanol
(v:v, final concentration). Carboxy-terminal GLP-1 immunoreac-
tivity was determined using antiserum 89390, which has an
absolute requirement for the intact amidated carboxyl terminus of
GLP-1 7–36 amide and cross-reacts ,0.01% with carboxy-
terminally truncated fragments and 89% with GLP-1 9–36 amide,
the primary metabolite of DPP-4-mediated degradation. The sum
of the two components, total GLP-1 concentration, reflects the
rate of secretion of the L-cell [9]. Active GLP-1 was analyzed using
an enzyme-linked immunosorbent assay on unextracted plasma, as
reported previously [8].
Statistical analysis
Area under the curve (AUC) of postprandial glucose, insulin,
insulin-to-glucose ratio, total and active GLP-1 concentrations
were calculated using the trapezoidal rule. Insulin data were
log10-transformed prior to statistical analysis. All values are
presented as means 6 standard deviation (SD), unless stated
otherwise. An a priori power analysis for the ANOVA repeated
measures within-between interaction design (a=0.05, power = 0.8)
was performed (G*Power version 3.0.10) giving a minimum sample
size of 6. The effects of the 4 week supplementation of glutamine
Figure 2. Study timeline. The effect of glutamine with sitagliptin or placebo was assessed in a randomized crossover study. Each study period (A
and B) was initiated with 2-weeks lead-in followed by L-glutamine (Gln) 15 g with breakfast and dinner with either sitagliptin (Sit; 100 mg) or placebo
for 4 weeks. Participants visited the Clinical Research Facility at day 0 (Baseline) and 4-weeks of studies A and B for a meal challenge. Treatments were
randomly assigned with a 4–6 week washout period between A and B studies.
doi:10.1371/journal.pone.0113366.g002
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with sitagliptin or glutamine with placebo were analyzed using
repeated measure ANOVA. For this, the within subject factor was
time – detecting differences in measured endpoints at 4 weeks
supplementation compared to baseline. The between subjects factor
was the treatment (supplementation) type – either glutamine with
sitagliptin or glutamine with placebo. The significance (P-values) for
both the within subject factor (time), and the interaction of time and
treatment is reported. Normal probability plots of the P-values
versus their rank were then examined to determine statistical
significance (not shown). Relationships that were found to be non-
linear were indicative of statistically significant results. The data
below P of 0.05 were in the non-linear regions. Data were analyzed
using SPSS version 21.
Results
Cohort characteristics
Participants were 6566 years old with BMI 2864 kg/m2 on
average. Type 2 diabetes duration was 3.361.7 years, HbA1c
7.160.3% (5464 mmol/mol), fasting plasma glucose 7.161.0
mmol/L and glutamine 572667 mmol/L (range 444–677 mmol/L).
The effects of the treatments on HbA1c, fructosamine,
fasting plasma glucose and GLP-1
HbA1c and fructosamine decreased modestly, without signifi-
cant time-treatment interactions. Fasting plasma glucose did not
change significantly with the treatments, but there was a significant
time-treatment effect (Table 1).
Fasting total GLP-1 increased (4.562.8 and 6.562.3 pmol/L
with glutamine + placebo and 5.362.6 and 7.462.3 pmol/L with
glutamine + sitagliptin at baseline and 4-weeks respectively,
P=0.006), without a significant time-treatment interaction (P=1).
Fasting active GLP-1 also increased with both treatments (0.460.6
and 1.061.2 pmol/L with glutamine + placebo and 0.861.0 and
2.361.6 pmol/L with glutamine + sitagliptin at baseline and 4
weeks, respectively, P#0.001), without a significant time-treat-
ment interaction (P=0.1).
The effect of the treatments on postprandial blood
glucose, serum insulin and plasma total and active GLP-1
Postprandial glucose AUC decreased (P=0.008), with a
significant time-treatment effect (P=0.003, Figure 3A). Postpran-
dial insulin AUC increased (P,0.001), without a significant time-
treatment effect (P=1, Figure 3B). Insulin-to-glucose AUC
increased (P=0.001), with a significant time-treatment effect
(P=0.003, Figure 3C). Postprandial total GLP-1 AUC increased
(P=0.008, Figure 3D), without a significant time-treatment effect
(P=0.2) and active GLP-1 AUC increased (P,0.001), with a
significant time-treatment effect (P=0.001, Figure 3E).
The effects of the treatments on weight, blood pressure,
full blood count, electrolytes and renal and liver function
Weight, resting metabolic rate (RMR), respiratory quotient
(RQ), systolic and diastolic blood pressure were unchanged.
Resting heart rate decreased, without a significant time-treatment
effect (Table 1). WBC, RBC, Hb and Hct all decreased, without
significant time-treatment interactions (Table 2). There were no
effects on the red blood cell characteristics mean corpuscular
volume (MCV), mean corpuscular Hb (MCH), mean corpuscular
Hb concentration (MCHC) and red cell distribution width (RDW;
Table 2). Neutrophil count decreased, without significant time-
treatment interaction and lymphocyte count decreased with a
significant time-treatment interaction (Table 2). Total protein,
albumin, alkaline phosphatase and gamma-glutamyl transpepti-
dase (GGT) all decreased, without significant time-treatment
interactions, while alanine transaminase (ALT), aspartate trans-
aminase (AST) and bilirubin were unchanged (Table 2). There
were no significant changes in electrolytes, including sodium,
potassium, chloride and bicarbonate (Table 2). Blood urea
increased, without a significant time-treatment interaction, but
creatinine, and therefore estimated glomerular filtration rate
(eGFR), were unchanged (Table 2).
Diet and physical activity during the study
Dietary intake of protein-rich food was not different between
baseline and 4-weeks (P=0.6) or between treatment periods
Table 1. Effects of the treatments on glycemic markers, weight and blood pressure.
Glutamine + Placebo Glutamine + Sitagliptin P value1
Baseline 4-weeks Baseline 4-weeks Time
Time-Treatment
interaction
HbA1c (%) 7.060.4 6.960.4 6.960.3 6.760.3 0.007 0.4
HbA1c (mmol/mol) 5364.3 5264.3 5263.6 5063.6
Fructosamine (mmol/L) 258640 244641 246632 240630 0.02 0.4
Fasting plasma glucose (mmol/L) 7.160.8 7.360.9 7.261.0 6.760.8 0.1 0.003
Weight (kg) 82.8615.7 82.9615.6 82.9615.1 82.7615.3 0.8 0.4
RMR (kcal/d) 15106300 14806320 14906330 15406400 0.8 0.3
Respiratory quotient 0.8060.04 0.8160.03 0.8160.04 0.8160.03 0.7 0.5
Systolic blood pressure (mmHg) 138617 137611 139616 13469 0.2 0.5
Diastolic blood pressure (mmHg) 8469 8467 84612 7966 0.2 0.2
Heart rate (bpm) 7168 6769 71610 6966 0.02 0.4
Data are means 6 SD.
RMR, resting metabolic rate.
1Significance of the repeated measure ANOVA with time (within subjects factor) and the interaction of time with treatments (the between subjects factor) is given
(n = 13). Bold values represent P,0.05. Normal probability plots of the P-values versus their rank were examined to determine statistical significance. Relationships that
were found to be non-linear were indicative of statistically significant results. The data below P of 0.05 were in the non-linear regions.
doi:10.1371/journal.pone.0113366.t001
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(P=0.7). Participants were sedentary and physical activity levels
were not different at baseline and 4-weeks (P=0.3) or between
treatment periods (243614 and 245615 metabolic equivalent of
tasks (METs) hr/week for glutamine + placebo and 249618 and
242616 METs hr/week for glutamine + sitagliptin at baseline and
4-weeks respectively, P=0.1).
Discussion
Daily ingestion of L-glutamine, with or without sitagliptin, for 4
weeks decreased HbA1c and fructosamine in well-controlled type
2 diabetes patients treated with metformin. However, glutamine
treatment was also associated with modest decreases in concen-
trations of circulating blood cells, total protein and albumin,
without changes in body weight or plasma electrolytes, suggesting
mild plasma volume expansion.
Both glycemic control markers, the longer term HbA1c and the
shorter term fructosamine decreased significantly with the
treatments in the present study, without a significant difference
between treatments. These findings suggest that the reduction in
glycaemia was attributed to the glutamine. Notably, HbA1c
reduction is expected to be larger if treatment was prolonged as
the treatment period of 28 days is under the mean red blood cell
age of about 50 days [10]. Fructosamine was added to the panel of
glycemic markers because of its shorter half-life. The meal studies
revealed that the combined glutamine and sitagliptin treatment
was more effective in decreasing postprandial glycaemia and in
increasing insulin-to-glucose ratio and active GLP-1. Accordingly,
we predict that longer treatments would have likely resulted in
more pronounced decreases in glycemic control markers with the
combined glutamine-sitagliptin treatment. This is also in line with
the decreases in fasting plasma glucose only with the sitagliptin
combination, potentially attributed to glucagon inhibition [7,8,11].
Importantly, reductions in the proportion of HbA1c are unaffected
by plasma volume expansion, however decreases in fructosamine
may have been affected by the general decreases in circulating
proteins in the present study.
Safety of glutamine supplementation of enteral or parenteral
nutrition was widely studied in critically-ill patients where L-
glutamine is used to maintain intestinal integrity, improve nitrogen
balance, prevent infections, decrease oxidative stress and improve
survival [12]. Glutamine supplementation in critically-ill patients
resulted in conflicting findings, including decreased [12], increased
[13] or no effect [14] on complications and mortality rates. Type 2
diabetes has been associated with decreases in circulating
glutamine previously [15] but, in this well-controlled diabetic
cohort plasma glutamine concentrations were within the reference
range [15,16]. Glutamine supplementation at levels of 1–30 g/d
are safe for several hours post ingestion in physically active healthy
populations [16] and type 2 diabetes patients [8]. However, safety
data of prolonged glutamine intake in non-critically-ill patients are
scarce. Galera and colleagues [17] investigated the safety of 14
Figure 3. The effect of glutamine + sitagliptin and glutamine +
placebo on postprandial circulating concentrations of glucose,
insulin and glucagon-like peptide-1. Postprandial circulating
concentrations of blood glucose (A), serum insulin (B), insulin to
glucose ratio (C) and plasma total and active GLP-1 (D and E,
respectively) at baseline (day 0; empty symbols) and 4-weeks (dark
symbols) of glutamine + sitagliptin (Gln + Sit; squares) and glutamine +
placebo (Gln + Placebo; circles) in type 2 diabetes patients (n = 13). Data
are means 6 SEM. Significance of the repeated measure ANOVA with
time (within subjects factor, **P,0.01) and the interaction of time with
treatments (the between subjects factor, ##P#0.01) in the AUC is given
(n = 13).
doi:10.1371/journal.pone.0113366.g003
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days of glutamine or casein supplementation in healthy, predom-
inantly sedentary, middle age and elderly individuals in dosages
slightly higher than those administered here (0.5 g/kg/d). Unlike
the present study, serum creatinine concentrations increased and
eGFR decreased with glutamine or casein [17], maybe due to the
higher protein intake. Similarly to the present study however,
blood urea concentrations increased [17], reflecting the increased
dietary nitrogen intake. Interestingly, blood cells, Hb, Hct, total
protein and albumin concentrations were all decreased with
glutamine in the present study. The decreases in red blood cells
without changes in MCV, MCH and MCHC and the general
decreases in circulating macromolecules suggest intravascular fluid
volume expansion, an effect previously documented in piglets with
parenteral glutamine supplementation [18]. Notably, body weight
and plasma electrolytes were unchanged in the present study,
consistent with minor changes in plasma volume or changes in
fluid distribution. The mechanisms involved in extracellular fluid
volume expansion with glutamine are unclear, but have been
suggested to involve increased glomerular sodium reabsorption
[18], which with prolonged glutamine ingestion may alter
electrolyte concentrations and acid-base regulation. Furthermore,
modest decreases in Hb and Hct were also noted previously with
high dose glutamine or casein supplementation for 14 days in
healthy individuals [17], suggesting that these effects are not
limited to glutamine or type 2 diabetes patients. In any case,
further study is required to determine the mechanisms involved in
the effect of glutamine on plasma volume expansion.
This is the first study to evaluate the effect of daily glutamine
supplementation for a period of weeks on glycemic control and
safety in type 2 diabetes patients. There are several strengths to the
study, including the sitagliptin versus placebo crossover design that
enabled investigation of possible interaction between glutamine
and DPP-4 inhibition. Furthermore, the homogeneity of the
cohort in terms of age, disease duration and background diabetes
treatment increased the power to detect the effects of the treatment
on the endpoints. The main limitation of the study is the lack of
sitagliptin-alone arm. Furthermore, the relatively low baseline
Table 2. Effects of the treatments on full blood count, renal and liver function and plasma electrolytes.
Marker (normal range) Glutamine + Placebo Glutamine + Sitagliptin P value
1
Baseline 4-weeks Baseline 4-weeks Time
Time-Treatment
interaction
WBC (4.0–11.0 .109/L) 6.261.5 5.861.2 6.361.5 5.561.8 0.004 0.4
RBC (4.5–6.5 .1012/L) 4.360.4 4.160.3 4.360.3 4.160.3 0.003 0.7
Hemoglobin (130–180 g/L) 135613 129610 134612 129611 0.001 0.8
Hematocrit (0.40–0.54%) 0.4060.04 0.3860.03 0.3960.03 0.3860.03 0.001 0.9
MCV (76–96 fL) 9264 9263 9264 9164 0.8 0.4
MCH (27.0–32.0 pg) 31.261.5 31.361.5 31.361.4 31.261.4 0.6 0.3
MCHC (320–360 g/L) 34065 34166 34265 34264 0.5 0.7
RDW (11.5–14.5%) 13.360.5 13.360.6 13.260.6 13.360.7 0.6 0.9
Platelets (150–400 109/L) 245666 240654 252656 240658 0.1 0.4
Neutrophils (2.0–7.5 109/L) 3.661.0 3.360.8 3.761.0 3.361.5 0.05 0.7
Lymphocytes (1.5–4.0 109/L) 1.860.6 1.860.6 1.960.5 1.660.5 0.003 0.01
Monocytes (0.2–1.0 109/L) 0.660.2 0.560.1 0.560.2 0.560.1 0.08 0.1
Total protein (60–82 g/L) 7064 6565 6964 6764 ,0.001 0.1
Albumin (36–52 g/L) 4562 4363 4562 4461 0.02 0.4
Alkaline phosphatase (30–100 U/L) 62621 58617 64619 57618 ,0.001 0.2
GGT (0–35 U/L) 25613 22611 25617 22613 0.01 0.7
ALT (0–30 U/L) 29611 27610 26612 2468 0.08 0.9
AST (0–30 U/L) 2668 2569 2366 2266 0.4 1
Total bilirubin (0–18 mmol/L) 1167 964 1066 1066 0.2 0.02
Sodium (137–146 mmol/L) 14262 14262 14162 14162 0.5 0.4
Potassium (3.5–5.0 mmol/L) 4.460.3 4.460.3 4.760.3 4.560.2 0.2 0.4
Chloride (95–110 mmol/L) 10463 10564 10462 10462 0.7 0.2
Bicarbonate (24–31 mmol/L) 2662 2662 2762 2662 0.2 0.9
Urea (3.0–8.5 mmol/L) 6.161.1 7.462.0 6.460.9 7.861.5 ,0.001 0.8
Creatinine (60–120 mmol/L) 76617 73613 75614 76614 0.6 0.2
eGFR (mL/min/1.73 m2) 80613 81611 81610 81610 0.5 0.6
Data are means 6 SD.
WBC, white blood cells; RBC, red blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration; RDW, red cell distribution width; GGT, gamma-glutamyl transpeptidase; ALT, alanine transaminase; AST, aspartate transaminase.
1Significance of the repeated measure ANOVA with time (within subjects factor) and the interaction of time with treatments (the between subjects factor) is given
(n = 13). Bold values represent P,0.05. Normal probability plots of the P-values versus their rank were examined to determine statistical significance. Relationships that
were found to be non-linear were indicative of statistically significant results. The data below P of 0.05 were in the non-linear regions.
doi:10.1371/journal.pone.0113366.t002
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HbA1c and short study duration may have limited the magnitude
of change in outcome measures.
In conclusion, daily glutamine administration for 4 weeks
decreased HbA1c, irrespective of sitagliptin treatment in well-
controlled type 2 diabetes patients treated with metformin.
Glutamine administration also resulted in an apparent plasma
volume expansion in this population and requires further study.
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